BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 20390697)

  • 1. Favorable mortality profile of naltrexone implants for opiate addiction.
    Reece AS
    J Addict Dis; 2010 Jan; 29(1):30-50. PubMed ID: 20390697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative treatment and mortality correlates and adverse event profile of implant naltrexone and sublingual buprenorphine.
    Reece AS
    J Subst Abuse Treat; 2009 Oct; 37(3):256-65. PubMed ID: 19394789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mortality related to pharmacotherapies for opioid dependence: a comparative analysis of coronial records.
    Gibson AE; Degenhardt LJ
    Drug Alcohol Rev; 2007 Jul; 26(4):405-10. PubMed ID: 17564876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD).
    Digiusto E; Shakeshaft A; Ritter A; O'Brien S; Mattick RP;
    Addiction; 2004 Apr; 99(4):450-60. PubMed ID: 15049745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Examination of mortality rates in a retrospective cohort of patients treated with oral or implant naltrexone for problematic opiate use.
    Kelty E; Hulse G
    Addiction; 2012 Oct; 107(10):1817-24. PubMed ID: 22487087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical treatment of opioid addiction and dependence.
    Ling W; Rawson RA; Compton M
    Methods Mol Med; 2003; 84():285-95. PubMed ID: 12703332
    [No Abstract]   [Full Text] [Related]  

  • 7. A Retrospective Cohort Study of Obstetric Outcomes in Opioid-Dependent Women Treated with Implant Naltrexone, Oral Methadone or Sublingual Buprenorphine, and Non-Dependent Controls.
    Kelty E; Hulse G
    Drugs; 2017 Jul; 77(11):1199-1210. PubMed ID: 28536980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mortality in heroin users 3 years after naltrexone implant or methadone maintenance treatment.
    Tait RJ; Ngo HT; Hulse GK
    J Subst Abuse Treat; 2008 Sep; 35(2):116-24. PubMed ID: 17931824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Limited role of naltrexone in the treatment of opiate addiction].
    van Brussel GH
    Ned Tijdschr Geneeskd; 2001 Jul; 145(30):1452-6. PubMed ID: 11503313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exposure to opioid maintenance treatment reduces long-term mortality.
    Gibson A; Degenhardt L; Mattick RP; Ali R; White J; O'Brien S
    Addiction; 2008 Mar; 103(3):462-8. PubMed ID: 18190664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone.
    Hulse GK; Morris N; Arnold-Reed D; Tait RJ
    Arch Gen Psychiatry; 2009 Oct; 66(10):1108-15. PubMed ID: 19805701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Retrospective Cohort Study of Birth Outcomes in Neonates Exposed to Naltrexone in Utero: A Comparison with Methadone-, Buprenorphine- and Non-opioid-Exposed Neonates.
    Kelty E; Hulse G
    Drugs; 2017 Jul; 77(11):1211-1219. PubMed ID: 28536981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naltrexone implant treatment for buprenorphine dependence--Mauritian case series.
    Jhugroo A; Ellayah D; Norman A; Hulse G
    J Psychopharmacol; 2014 Aug; 28(8):800-3. PubMed ID: 24695742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved.
    Degenhardt L; Randall D; Hall W; Law M; Butler T; Burns L
    Drug Alcohol Depend; 2009 Nov; 105(1-2):9-15. PubMed ID: 19608355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fatal and non-fatal opioid overdose in opioid dependent patients treated with methadone, buprenorphine or implant naltrexone.
    Kelty E; Hulse G
    Int J Drug Policy; 2017 Aug; 46():54-60. PubMed ID: 28609749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of opioid dependence in adolescents and young adults with extended release naltrexone: preliminary case-series and feasibility.
    Fishman MJ; Winstanley EL; Curran E; Garrett S; Subramaniam G
    Addiction; 2010 Sep; 105(9):1669-76. PubMed ID: 20626723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opioid-dependent error processing.
    Fellows-Smith J
    J Opioid Manag; 2011; 7(6):443-9. PubMed ID: 22320026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing drug-related hospital morbidity following heroin dependence treatment with methadone maintenance or naltrexone implantation.
    Ngo HT; Tait RJ; Hulse GK
    Arch Gen Psychiatry; 2008 Apr; 65(4):457-65. PubMed ID: 18391134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Depot naltrexone use for opioid dependence in Australia: large-scale use of an unregistered medication in the absence of data on safety and efficacy.
    Degenhardt L; Gibson A; Mattick RP; Hall W
    Drug Alcohol Rev; 2008 Jan; 27(1):1-3. PubMed ID: 18034375
    [No Abstract]   [Full Text] [Related]  

  • 20. [Naltrexone and opiate substitutive treatment].
    Dupouy J; Poutrain JC; Lapeyre-Mestre M
    Therapie; 2011; 66(6):549-52. PubMed ID: 22691393
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.